Lilly Raised Guidance as Zepbound Soars - Oct 29

The Big Picture

Investors are taking notice: Eli Lilly raised sales guidance for the third time this year as Zepbound sales soar, and the company topped third-quarter expectations. Shares of Eli Lilly and (LLY) are trading near $91 to $92, showing a modest intraday uptick of about 0.02% while the stock has posted much larger gains this year.

The guidance raise and a 39% jump in Q3 revenue makes this one of the clearest near-term growth stories in big pharma, with immediate implications for portfolios that hold growth and healthcare exposure.

What's Happening

Lilly reported a strong third quarter and updated its outlook on Oct 29, according to Reuters and MarketWatch reporting. The results and guidance move center on demand for its weight-loss and diabetes drugs, led by Zepbound and Mounjaro.

• Revenue in Q3 2026 increased 39% to $24.4 billion, driven primarily by Mounjaro and Zepbound, a key growth engine.
• The company raised full-year revenue guidance for the third time this year, citing stronger-than-expected sales momentum.
• Shares have rallied sharply this year, with one reported performance snapshot of about 44.57% year-to-date gains.
• Shorter-term strength was reflected in recent moves of roughly 20.24% over a nearer-term window and an intraday change near 0.02% as markets absorbed the update.

The Q3 beat and updated guidance are concrete signs the prescription weight-loss market continues to favor Lilly. MarketWatch noted the company’s dominance in the U.S. prescription weight-loss segment, and Reuters flagged the revenue forecast raise alongside the earnings beat.

Why It Matters For Your Portfolio

This matters because the guidance raise signals durable demand for Lilly’s obesity and diabetes franchise, which can support further earnings upgrades and valuation re-rating for $LLY. Growth investors will want to reassess model assumptions around Zepbound adoption curves and margin contribution.

Income or value investors should note that the company’s top-line acceleration can create optionality for share-buybacks or payout policy changes, but those outcomes are not guaranteed. Traders will watch reaction to near-term catalysts for volatility.

Risks To Consider

• Competitive and regulatory risk: The prescription weight-loss market is competitive and subject to regulatory scrutiny, which could slow adoption or change labeling and reimbursement dynamics.
• Execution and supply risk: Rapid demand ramps can produce supply-chain or margin pressures that compress realized profits despite strong revenue growth.
• Valuation sensitivity: The stock’s rally, reflected in strong percentage gains this year, leaves little margin for error if growth slows; a downside scenario could push shares materially lower from current levels near $91 to $92.

What To Watch Next

Investors should monitor upcoming company and sector events that could move the stock and test the sustainability of the current run.

• Follow-up comments from Lilly management on cadence and geography of Zepbound rollouts and supply expectations after the Oct 29 release.
• Analyst and consensus model updates that incorporate the third guidance raise and Q3 results, including revisions to revenue and margin forecasts.
• Key price levels: near-term trading around $91 to $92 and earlier reference points near $85.0 as a prior support area.

The Bottom Line

• Lilly raised sales guidance for the third time this year as Zepbound sales soar, and Q3 revenue rose 39% to $24.4B, signaling strong top-line momentum.
• The company beat third-quarter expectations and raised its full-year revenue forecast, according to Reuters and MarketWatch reporting on Oct 29.
• Shares are rallying, trading near $91 to $92 with intraday moves around 0.02% and sizable year-to-date gains reported; these moves increase sensitivity to any growth miss.
• Investors should watch management’s cadence comments, analyst revisions, and supply or regulatory developments before adjusting positions.
• Data suggests momentum, but risks around competition, execution, and valuation remain; use earnings and guidance details to reassess models rather than relying on headline momentum alone.

FAQ

Q: How big was Lilly's latest revenue beat?

A: Revenue in Q3 increased 39% to $24.4 billion, and the company raised its full-year revenue forecast for the third time this year, according to Reuters and MarketWatch.

Q: What drove the guidance raise?

A: Management cited strong sales of Mounjaro and Zepbound, with Zepbound sales described as soaring and driving U.S. prescription weight-loss market strength.

Q: What immediate market signals should I track?

A: Track management commentary after the Oct 29 report, analyst estimate revisions, and price support near prior levels around $85.0 while noting current trading around $91 to $92 and recent performance snapshots cited in reporting.

Disclosure: This article is informational only and does not constitute investment advice. Analysts note that reported figures and guidance changes should be incorporated into your own models and risk assessments before making any investment decision.